Incyte Corporation INCY presented final results today from the
Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1)
inhibitor, INCB024360, at the American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago. IDO1 inhibition may provide a new
approach in enhancing the immune system in patients with a variety of
solid tumors.
“IDO1 is an enzyme that works to restrain anti-tumor immunity. When IDO1
is activated in cancer patients with a number of tumor types, their
prognosis is poor. A compound such as INCB024360, which can
significantly inhibit IDO enzyme activity, may remove an important
impediment to an anti-tumor immune response at doses that appear to be
well-tolerated. IDO inhibition provides another immunotherapeutic
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in